Intellectual Property India Publishes Patent Application for 'Anti-Muc1 Antibodies And Uses Thereof' Filed by Biocytogen Pharmaceuticals (BEIJING) Co. Ltd.

MUMBAI, India, July 25 -- Intellectual Property India has published a patent application (202517067523 A) filed by Biocytogen Pharmaceuticals (BEIJING) Co. Ltd., Beijing, on July 15, for 'anti-muc1 antibodies and uses thereof.'

Inventor(s) include Zhang, Yifu; Shang, Chengzhang; Yang, Yi; and Shen, Yuelei.

The application for the patent was published on July 25, under issue no. 30/2025.

According to the abstract released by the Intellectual Property India: "Provided are anti-MUCl (Mucin 1, cell surface associated) antibodies, antigen-binding fragments thereof, antibody-drug conjugate (ADC) derived therefrom, and the uses thereof."

The patent application was internationally filed on Jan. 03, 2024, under International application No.PCT/CN2024/070253.

Disclaimer: Curated by HT Syndication.